| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case study of lean drug discovery: from project driven research to innovation studios and process factories
|
Ullman, Fredrik
|
|
2008
|
|
11-12 |
p. 543-550
8 p.
|
artikel
|
| 2 |
A new member in the real-time PCR menagerie: the Snake assay
|
Demidov, Vadim V.
|
|
2010
|
|
11-12 |
p. 493-
1 p.
|
artikel
|
| 3 |
An infrastructure for interconnecting research institutions
|
Buetow, Kenneth H.
|
|
2009
|
|
11-12 |
p. 605-610
6 p.
|
artikel
|
| 4 |
Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?
|
Rayburn, Elizabeth R.
|
|
2008
|
|
11-12 |
p. 513-521
9 p.
|
artikel
|
| 5 |
A perspective of publicly accessible/open-access chemistry databases
|
Williams, Antony J.
|
|
2008
|
|
11-12 |
p. 495-501
7 p.
|
artikel
|
| 6 |
Application of technologies and parallel chemistry for the generation of actives against biological targets
|
Edwards, Paul
|
|
2008
|
|
11-12 |
p. 551-552
2 p.
|
artikel
|
| 7 |
Auto-associative amphiphilic polysaccharides as drug delivery systems
|
Hassani, Leila N.
|
|
2012
|
|
11-12 |
p. 608-614
7 p.
|
artikel
|
| 8 |
Automated medicinal chemistry
|
Koppitz, Marcus
|
|
2006
|
|
11-12 |
p. 561-568
8 p.
|
artikel
|
| 9 |
Bayesian versus Frequentist statistical modeling: A debate for hit selection from HTS campaigns
|
Cloutier, L. Martin
|
|
2008
|
|
11-12 |
p. 536-542
7 p.
|
artikel
|
| 10 |
Biophysical microenvironment and 3D culture physiological relevance
|
Asthana, Amish
|
|
2013
|
|
11-12 |
p. 533-540
8 p.
|
artikel
|
| 11 |
Catechins containing a galloyl moiety as potential anti-HIV-1 compounds
|
Zhao, Yali
|
|
2012
|
|
11-12 |
p. 630-635
6 p.
|
artikel
|
| 12 |
Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases
|
Chène, Patrick
|
|
2008
|
|
11-12 |
p. 522-529
8 p.
|
artikel
|
| 13 |
Chemoproteomics-driven drug discovery: addressing high attrition rates
|
Hall, Steven E.
|
|
2006
|
|
11-12 |
p. 495-502
8 p.
|
artikel
|
| 14 |
Combinatorial Domain Hunting: solving problems in protein expression
|
Littler, Eddy
|
|
2010
|
|
11-12 |
p. 461-467
7 p.
|
artikel
|
| 15 |
Commercial pigs: an untapped resource for human obesity research?
|
Rocha, Dominique
|
|
2006
|
|
11-12 |
p. 475-477
3 p.
|
artikel
|
| 16 |
Contents
|
|
|
2010
|
|
11-12 |
p. iii-
1 p.
|
artikel
|
| 17 |
Contents
|
|
|
2010
|
|
11-12 |
p. i-
1 p.
|
artikel
|
| 18 |
Contents
|
|
|
2013
|
|
11-12 |
p. iii-
1 p.
|
artikel
|
| 19 |
Contents
|
|
|
2013
|
|
11-12 |
p. i-
1 p.
|
artikel
|
| 20 |
Contents
|
|
|
2012
|
|
11-12 |
p. i-
1 p.
|
artikel
|
| 21 |
Contents
|
|
|
2012
|
|
11-12 |
p. iii-
1 p.
|
artikel
|
| 22 |
Contents page 2
|
|
|
2008
|
|
11-12 |
p. iii-
1 p.
|
artikel
|
| 23 |
Contents page 1
|
|
|
2008
|
|
11-12 |
p. i-
1 p.
|
artikel
|
| 24 |
Contents page 2
|
|
|
2009
|
|
11-12 |
p. iii-
1 p.
|
artikel
|
| 25 |
Contents page 1
|
|
|
2009
|
|
11-12 |
p. i-
1 p.
|
artikel
|
| 26 |
Contents page 2
|
|
|
2011
|
|
11-12 |
p. iii-
1 p.
|
artikel
|
| 27 |
Contents page 1
|
|
|
2011
|
|
11-12 |
p. i-
1 p.
|
artikel
|
| 28 |
Contribution of structural biology to clinically validated target proteins
|
Mori, Masumi
|
|
2008
|
|
11-12 |
p. 469-472
4 p.
|
artikel
|
| 29 |
Current developments of macrophage migration inhibitory factor (MIF) inhibitors
|
Xu, Lei
|
|
2013
|
|
11-12 |
p. 592-600
9 p.
|
artikel
|
| 30 |
Deploying continuous improvement across the drug discovery value chain
|
Walker, Stephen M.
|
|
2011
|
|
11-12 |
p. 467-471
5 p.
|
artikel
|
| 31 |
Diary/ Issue 11
|
|
|
2006
|
|
11-12 |
p. 571-
1 p.
|
artikel
|
| 32 |
Diving for drugs: tunicate anticancer compounds
|
Cooper, Edwin L.
|
|
2012
|
|
11-12 |
p. 636-648
13 p.
|
artikel
|
| 33 |
Dopamine-sensitive adenylyl cyclases in neuronal development: physiopathological and pharmacological implications
|
Pavan, Barbara
|
|
2011
|
|
11-12 |
p. 520-529
10 p.
|
artikel
|
| 34 |
Drug discovery management, small is still beautiful: Why a number of companies get it wrong
|
Knutsen, Lars J.S.
|
|
2011
|
|
11-12 |
p. 476-484
9 p.
|
artikel
|
| 35 |
Drug-induced arrhythmias and sudden cardiac death: implications for the pharmaceutical industry
|
Killeen, Matthew J.
|
|
2009
|
|
11-12 |
p. 589-597
9 p.
|
artikel
|
| 36 |
3D structures and ligand specificities of nuclear xenobiotic receptors CAR, PXR and VDR
|
Wu, Baojian
|
|
2013
|
|
11-12 |
p. 574-581
8 p.
|
artikel
|
| 37 |
Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies
|
Fitzgerald, Mary F.
|
|
2007
|
|
11-12 |
p. 472-478
7 p.
|
artikel
|
| 38 |
Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development
|
Fitzgerald, Mary F.
|
|
2007
|
|
11-12 |
p. 479-486
8 p.
|
artikel
|
| 39 |
Endocannabinoid biosynthesis and inactivation, from simple to complex
|
Muccioli, Giulio G.
|
|
2010
|
|
11-12 |
p. 474-483
10 p.
|
artikel
|
| 40 |
Evolving molecules using multi-objective optimization: applying to ADME/Tox
|
Ekins, Sean
|
|
2010
|
|
11-12 |
p. 451-460
10 p.
|
artikel
|
| 41 |
Finding Hsp90 inhibitors by drug repurposing: The power of chemical genetics
|
Xiong, Min
|
|
2012
|
|
11-12 |
p. 531-533
3 p.
|
artikel
|
| 42 |
Fluorine magnetic resonance in vivo: A powerful tool in the study of drug distribution and metabolism
|
Reid, David G.
|
|
2008
|
|
11-12 |
p. 473-480
8 p.
|
artikel
|
| 43 |
Fragment-based drug discovery of carbonic anhydrase II inhibitors by dynamic combinatorial chemistry
|
Edwards, Paul
|
|
2007
|
|
11-12 |
p. 497-498
2 p.
|
artikel
|
| 44 |
From East to West: A Japanese Pharma perspective on establishing a global research capability
|
Takatani, Muneo
|
|
2009
|
|
11-12 |
p. 611-617
7 p.
|
artikel
|
| 45 |
Functionalized carbon nanotubes for potential medicinal applications
|
Zhang, Yi
|
|
2010
|
|
11-12 |
p. 428-435
8 p.
|
artikel
|
| 46 |
Global challenges in the development and delivery of paediatric antiretrovirals
|
Bowen, Asha
|
|
2008
|
|
11-12 |
p. 530-535
6 p.
|
artikel
|
| 47 |
G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery
|
Milligan, Graeme
|
|
2006
|
|
11-12 |
p. 541-549
9 p.
|
artikel
|
| 48 |
Health economics and outcomes research within drug development
|
van Nooten, Floortje
|
|
2012
|
|
11-12 |
p. 615-622
8 p.
|
artikel
|
| 49 |
Heat shock proteins as vaccine adjuvants in infections and cancer
|
Segal, Brahm H.
|
|
2006
|
|
11-12 |
p. 534-540
7 p.
|
artikel
|
| 50 |
Helping secure the global pharmaceutical manufacturing supply chain
|
Lawson, Marcus
|
|
2009
|
|
11-12 |
p. 533-535
3 p.
|
artikel
|
| 51 |
High-content multiplexed tissue imaging and quantification for cancer drug discovery
|
Falcon, Beverly L.
|
|
2013
|
|
11-12 |
p. 510-522
13 p.
|
artikel
|
| 52 |
Histone acetyltransferases are crucial regulators in NF-κB mediated inflammation
|
Ghizzoni, Massimo
|
|
2011
|
|
11-12 |
p. 504-511
8 p.
|
artikel
|
| 53 |
How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue
|
Giraldo, Jesús
|
|
2010
|
|
11-12 |
p. 411-415
5 p.
|
artikel
|
| 54 |
How to conduct and interpret ITC experiments accurately for cyclodextrin–guest interactions
|
Bouchemal, Kawthar
|
|
2012
|
|
11-12 |
p. 623-629
7 p.
|
artikel
|
| 55 |
Identifying and validating novel targets with in vivo disease models: Guidelines for study design
|
Anders, Hans-Joachim
|
|
2007
|
|
11-12 |
p. 446-451
6 p.
|
artikel
|
| 56 |
Immunocytokines: a novel class of potent armed antibodies
|
Pasche, Nadine
|
|
2012
|
|
11-12 |
p. 583-590
8 p.
|
artikel
|
| 57 |
Influenza therapies: vaccines and antiviral drugs
|
Quigley, Emma
|
|
2006
|
|
11-12 |
p. 478-480
3 p.
|
artikel
|
| 58 |
Informatics solutions for high-throughput proteomics
|
Topaloglou, Thodoros
|
|
2006
|
|
11-12 |
p. 509-516
8 p.
|
artikel
|
| 59 |
Internet-based tools for communication and collaboration in chemistry
|
Williams, Antony J.
|
|
2008
|
|
11-12 |
p. 502-506
5 p.
|
artikel
|
| 60 |
I want a new drug: G-protein-coupled receptors in drug development
|
Schlyer, Sabine
|
|
2006
|
|
11-12 |
p. 481-493
13 p.
|
artikel
|
| 61 |
June Diary
|
|
|
2007
|
|
11-12 |
p. 499-
1 p.
|
artikel
|
| 62 |
Lead discovery by DNA-encoded chemical libraries
|
Melkko, Samu
|
|
2007
|
|
11-12 |
p. 465-471
7 p.
|
artikel
|
| 63 |
Light-activated antibodies in the fight against primary and metastatic cancer
|
Thompson, Stephen
|
|
2010
|
|
11-12 |
p. 468-473
6 p.
|
artikel
|
| 64 |
Making medicinal chemistry more effective—application of Lean Sigma to improve processes, speed and quality
|
Andersson, Shalini
|
|
2009
|
|
11-12 |
p. 598-604
7 p.
|
artikel
|
| 65 |
Medicinal chemistry matters – a call for discipline in our discipline
|
Johnstone, Craig
|
|
2012
|
|
11-12 |
p. 538-543
6 p.
|
artikel
|
| 66 |
Medicinal chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents
|
|
|
2006
|
|
11-12 |
p. 494-
1 p.
|
artikel
|
| 67 |
Models for predicting blood–brain barrier permeation
|
Nielsen, Peter Aadal
|
|
2011
|
|
11-12 |
p. 472-475
4 p.
|
artikel
|
| 68 |
Modular pharmacology: deciphering the interacting structural organization of the targeted networks
|
Wang, Zhong
|
|
2013
|
|
11-12 |
p. 560-566
7 p.
|
artikel
|
| 69 |
Monoclonal antibodies for chronic refractory asthma and pipeline developments
|
Polosa, Riccardo
|
|
2012
|
|
11-12 |
p. 591-599
9 p.
|
artikel
|
| 70 |
Nano bioresearch approach by microtechnology
|
Collard, Dominique
|
|
2013
|
|
11-12 |
p. 552-559
8 p.
|
artikel
|
| 71 |
Natural and synthetic α-methylenelactones and α-methylenelactams with anticancer potential
|
Janecka, Anna
|
|
2012
|
|
11-12 |
p. 561-572
12 p.
|
artikel
|
| 72 |
Natural antisense and noncoding RNA transcripts as potential drug targets
|
Wahlestedt, Claes
|
|
2006
|
|
11-12 |
p. 503-508
6 p.
|
artikel
|
| 73 |
Natural products as lead-structures: a role for biotechnology
|
John, Jacob E.
|
|
2010
|
|
11-12 |
p. 409-410
2 p.
|
artikel
|
| 74 |
Network medicine in drug design: implications for neuroinflammation
|
Ghosh, Sourish
|
|
2012
|
|
11-12 |
p. 600-607
8 p.
|
artikel
|
| 75 |
New developments in synthetic peroxidic drugs as artemisinin mimics
|
Jefford, Charles W.
|
|
2007
|
|
11-12 |
p. 487-495
9 p.
|
artikel
|
| 76 |
New strategies to improve the intranasal absorption of insulin
|
Duan, Xiaopin
|
|
2010
|
|
11-12 |
p. 416-427
12 p.
|
artikel
|
| 77 |
New tools and approaches for predicting skin permeability
|
Degim, I.Tuncer
|
|
2006
|
|
11-12 |
p. 517-523
7 p.
|
artikel
|
| 78 |
Nonsymmetrical cyclic urea inhibitors of HIV-1 aspartic protease
|
Edwards, Paul
|
|
2006
|
|
11-12 |
p. 569-570
2 p.
|
artikel
|
| 79 |
Orphan nuclear receptors in drug discovery
|
Shi, Yanhong
|
|
2007
|
|
11-12 |
p. 440-445
6 p.
|
artikel
|
| 80 |
Outsourcing to exploit a key asset
|
Meerpoel, Lieven
|
|
2006
|
|
11-12 |
p. 556-560
5 p.
|
artikel
|
| 81 |
Phage therapy
|
Housby, John N.
|
|
2009
|
|
11-12 |
p. 536-540
5 p.
|
artikel
|
| 82 |
Pharmacophore modeling and applications in drug discovery: challenges and recent advances
|
Yang, Sheng-Yong
|
|
2010
|
|
11-12 |
p. 444-450
7 p.
|
artikel
|
| 83 |
Prediction of microRNA targets
|
Mazière, Pierre
|
|
2007
|
|
11-12 |
p. 452-458
7 p.
|
artikel
|
| 84 |
Predictive methods in drug repurposing: gold mine or just a bigger haystack?
|
Cavalla, David
|
|
2013
|
|
11-12 |
p. 523-532
10 p.
|
artikel
|
| 85 |
Pyrazole CCK1 receptor antagonists
|
Edwards, Paul
|
|
2007
|
|
11-12 |
p. 496-
1 p.
|
artikel
|
| 86 |
Reactions and enzymes in the metabolism of drugs and other xenobiotics
|
Testa, Bernard
|
|
2012
|
|
11-12 |
p. 549-560
12 p.
|
artikel
|
| 87 |
Should medicinal chemists do molecular modelling?
|
Ritchie, Timothy J.
|
|
2012
|
|
11-12 |
p. 534-537
4 p.
|
artikel
|
| 88 |
Should non-inferiority drug trials be banned altogether?
|
Wangge, Grace
|
|
2013
|
|
11-12 |
p. 601-604
4 p.
|
artikel
|
| 89 |
Spinal cord injury in vitro: modelling axon growth inhibition
|
Abu-Rub, Mohammad
|
|
2010
|
|
11-12 |
p. 436-443
8 p.
|
artikel
|
| 90 |
Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives
|
Ma, X.H.
|
|
2009
|
|
11-12 |
p. 579-588
10 p.
|
artikel
|
| 91 |
Targeted genetic and viral therapy for advanced head and neck cancers
|
Huang, Pin-I
|
|
2009
|
|
11-12 |
p. 570-578
9 p.
|
artikel
|
| 92 |
Targeted scoring functions for virtual screening
|
Seifert, Markus H.J.
|
|
2009
|
|
11-12 |
p. 562-569
8 p.
|
artikel
|
| 93 |
Targeting HIV latency: pharmacologic strategies toward eradication
|
Xing, Sifei
|
|
2013
|
|
11-12 |
p. 541-551
11 p.
|
artikel
|
| 94 |
Targeting neuronal adenylyl cyclase for the treatment of chronic pain
|
Zhuo, Min
|
|
2012
|
|
11-12 |
p. 573-582
10 p.
|
artikel
|
| 95 |
Targeting survivin in cancer: the cell-signalling perspective
|
Kanwar, Jagat R.
|
|
2011
|
|
11-12 |
p. 485-494
10 p.
|
artikel
|
| 96 |
Targeting the epithelial cells in fibrosis: a new concept for an old disease
|
Moll, Solange
|
|
2013
|
|
11-12 |
p. 582-591
10 p.
|
artikel
|
| 97 |
The application of next-generation sequencing technologies to drug discovery and development
|
Woollard, Peter M.
|
|
2011
|
|
11-12 |
p. 512-519
8 p.
|
artikel
|
| 98 |
The design and synthesis of focused parallel chemistry libraries for the discovery of biologically active substances
|
Edwards, Paul
|
|
2009
|
|
11-12 |
p. 618-620
3 p.
|
artikel
|
| 99 |
The dose makes the medicine
|
Stumpf, Walter E.
|
|
2006
|
|
11-12 |
p. 550-555
6 p.
|
artikel
|
| 100 |
The hidden quality gap in discovery
|
Hampton, David
|
|
2013
|
|
11-12 |
p. 506-509
4 p.
|
artikel
|
| 101 |
The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials
|
Muzzi, Alessandro
|
|
2007
|
|
11-12 |
p. 429-439
11 p.
|
artikel
|
| 102 |
The path to a successful vaccine adjuvant – ‘The long and winding road’
|
O’Hagan, Derek T.
|
|
2009
|
|
11-12 |
p. 541-551
11 p.
|
artikel
|
| 103 |
Therapeutic potential of anticancer immunotoxins
|
Choudhary, Swati
|
|
2011
|
|
11-12 |
p. 495-503
9 p.
|
artikel
|
| 104 |
The therapeutic and diagnostic potential of FKBPL; a novel anticancer protein
|
Robson, Tracy
|
|
2012
|
|
11-12 |
p. 544-548
5 p.
|
artikel
|
| 105 |
The therapeutic prospects of using l-carnitine to manage hypertension-related organ damage
|
Mate, Alfonso
|
|
2010
|
|
11-12 |
p. 484-492
9 p.
|
artikel
|
| 106 |
The Ukrainian pharmaceutical market
|
Bondaryev, Timur B.
|
|
2011
|
|
11-12 |
p. 465-466
2 p.
|
artikel
|
| 107 |
The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine
|
Foekens, John A.
|
|
2008
|
|
11-12 |
p. 481-487
7 p.
|
artikel
|
| 108 |
The value of the Semantic Web in the laboratory
|
Frey, Jeremy G.
|
|
2009
|
|
11-12 |
p. 552-561
10 p.
|
artikel
|
| 109 |
Tools for efficient high-throughput synthesis
|
Chighine, Alessandra
|
|
2007
|
|
11-12 |
p. 459-464
6 p.
|
artikel
|
| 110 |
Translational medicines research
|
Palmer, Alan M.
|
|
2013
|
|
11-12 |
p. 503-505
3 p.
|
artikel
|
| 111 |
Treatment of obesity as a potential complementary approach to cancer therapy
|
Sirin, Olga
|
|
2013
|
|
11-12 |
p. 567-573
7 p.
|
artikel
|
| 112 |
Use of genetically modified rat models for translational medicine
|
Cozzi, Jean
|
|
2008
|
|
11-12 |
p. 488-494
7 p.
|
artikel
|
| 113 |
Using ontogeny information to build predictive models for drug elimination
|
Alcorn, Jane
|
|
2008
|
|
11-12 |
p. 507-512
6 p.
|
artikel
|
| 114 |
Utility of protein structures in overcoming ADMET-related issues of drug-like compounds
|
Stoll, Friederike
|
|
2011
|
|
11-12 |
p. 530-538
9 p.
|
artikel
|
| 115 |
Vascular NADPH oxidases as drug targets for novel antioxidant strategies
|
Guzik, Tomasz J.
|
|
2006
|
|
11-12 |
p. 524-533
10 p.
|
artikel
|
Tijdschrift beschrijving